Inhibrx Biosciences, Inc. Common Stock (INBX) Stock Price
INBXStock
$89.83+145.47%52W
Market Cap$1.32B
P/E0.55x
PEG Ratio—
Div yield—
Beta3.18
INBX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-1.92%
Price vs S&P 500 (4W)-18.50%
VGM Score52.82
P/E Ratio (Annual)0.55x
INBX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$2.28 | -$2.34 | -2.63%(-$0.06) | |
| Q1 2026 | -$1.20 | -$2.15 | -79.17%(-$0.95) | |
| Q4 2025 | -$2.08 | -$2.11 | -1.44%(-$0.03) | |
| Q3 2025 | -$1.72 | -$2.28 | -32.56%(-$0.56) | |
| Q2 2025 | -$2.60 | -$1.85 | +28.85%(+$0.75) |
INBX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.11
4.11
4.11
4.10
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
INBXInhibrx Biosciences, Inc. Common Stock | D | C | A | 944.3x | 550.0% | — | — | $89.83 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Inhibrx Biosciences, Inc. Common Stock
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapies using its proprietary protein engineering platform. The company's pipeline includes INBRX-109 and INBRX-106, multivalent therapeutic candidates designed to optimize target engagement and agonist activity.